Option Care Announces Expansion Into Louisiana
By: Option Care
August 7, 2018
New Care Management Center Provides Expanded Access to Home Infusion
NEW ORLEANS, August 7, 2018 — Option Care Enterprises, Inc. (“Option Care”), the nation’s largest provider of home and alternate treatment site infusion therapy services, is expanding patient access to care with the opening of its first Care Management Center in Louisiana. The facility opened June 11 in Elmwood, La., introducing the company’s personalized clinical care to patients covered by national and regional health insurance plans.
Through the new Louisiana Care Management Center (“CMC”), Option Care’s dedicated team of clinicians, nurses, pharmacists, technicians and dietitians may now deliver home and alternate treatment site infusion services to patients who rely on infusion therapies for complex conditions including:
- Infectious diseases
- Nutritional and gastrointestinal disorders
- Advanced cardiac failure
- Primary immune deficiencies
- Hemophilia and bleeding disorders
- Autoimmune disorders
- End-stage organ failure
“Our expansion into Louisiana means that millions more patients now have access to Option Care’s specialized clinical care, supported by our national network of pharmacies and alternate treatment sites across the country,” said William Miller, RPh Clinical Director of Infectious Disease at Option Care. “Patients want access to quality, personalized care in the comfort of their own homes or the convenience of community-based alternate treatment sites. That’s what we deliver, ensuring seamless transitions of care from hospital to home and helping patients manage their health with greater ease and less worry.”
The new Louisiana CMC is led by senior staff who have significant clinical expertise and local experience with the delivery of critical healthcare services.
“We have an extensive knowledge of this area and are thrilled to be part of the team that is bringing Option Care’s services to patients who need these critical therapies,” said Mike Messonnier, MSPH, RPh Director of Operations at the Option Care Louisiana CMC. “Option Care is advancing the infusion care industry with technologies that support the highest levels of clinical excellence. We’re delighted to be providing these innovative services to patients in our community.”
The Louisiana CMC location will be equipped to deliver superior outcomes with Option Care’s state-of-the-art, technology-enabled, data-driven services and programs.
About Option Care
Option Care Enterprises, Inc. (Option Care) is the nation’s largest and most trusted provider of home and alternate treatment site infusion services. Holding accreditations from industry quality organizations ACHC, PCAB, ASHP and URAC,[*]Accreditation Commission for Health Care (ACHC), Pharmacy Compounding Accreditation Board (PCAB), American Society of Health-System Pharmacists (ASHP) and URAC. the company draws on nearly 40 years of clinical care experience to offer patient-centered therapy management. Option Care’s signature Home Infusion Plus services include the clinical management of infusion medicines, nursing support and care coordination. Option Care’s multidisciplinary team of more than 1,800 clinicians — including pharmacists, nurses and dietitians — are able to provide home infusion service coverage for nearly all patients across the United States needing treatment for complex and chronic conditions. Learn more at www.OptionCare.com.
You might also be interested in:
Option Care Selected to Provide First and Only Treatment Specifically for Hereditary Factor X Deficiency
DEERFIELD, Ill. — Option Care Enterprises, Inc., an independent infusion services company, has been selected as a contracted provider of Coagadex ® (Coagulation Factor X Human), the first and only treatment approved by the U.S. Food and Drug Administration specifically for hereditary factor X deficiency, a rare and serious bleeding disorder. Coagadex is manufactured by […]
Adverse Drug Events Rare Among Patients Receiving Home Infusion Autoimmune Therapy
NEW ORLEANS — Adverse drug events (ADE) were rare — and serious ADEs nonexistent — in a retrospective two-year study of nearly 1,900 home and alternate treatment site (ATS) infusions of infliximab for patients with autoimmune disorders.1 The research was presented today by Option Care, a leading provider of home and ATS infusion services, at […]